API | mirogabalin

mirogabalin Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Mirogabalin is a gabapentinoid medication developed by Daiichi Sankyo. Gabapentin and pregabalin are also members of this class. As a gabapentinoid, mirogabalin binds to the α2δ subunit of voltage-gated calcium channel, but with significantly higher potency than pregabalin. It has shown promising results in Phase II clinical trials for the treatment of diabetic peripheral neuropathic pain. ^Wikipedia

Chemistry

SMILES: CCC1=C[C@@H]2[C@H](C1)C[C@]2(CN)CC(=O)O
InChIKey: FTBQORVNHOIASH-CKYFFXLPSA-N
Mol. Mass: 209.29
ALogP: 1.78 Partition coefficient
ChEMBL Molecule:
mirogabalin

More Chemistry

Pharmacology

Mechanism of Action:
- Voltage-dependent calcium channel subunit alpha-2/delta-1 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

aminomethyl)-3-ethyl-bicyclo(3.2.0)hept-3-ene-6-acetic acid | ds-5565 | mirogabalin

Organizations (6)

Research & Development (6)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)

Diabetes Mellitus (Phase 2)

Fibromyalgia (Phase 3)

Neuralgia, Postherpetic (Phase 3)

Pain (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 13
# of Trial Organizations: 6

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue